Abstract:Background Although vascular calcification (VC) is a risk factor for cardiovascular and all-cause mortality, a therapy is not yet available. VC involves the transdifferentiation of vascular smooth muscle cells (VSMC) towards an osteochondrogenic lineage that results in calcium phosphate salts deposition in the arterial wall. We have previously shown an association between plasma WNT5A levels and new onset and progression of coronary artery calcification. Purpose We aimed to study the poorly understood role of Wnt5a in VSMC calcification. Methods Study 1 included 18 patients with coronary artery disease (CAD) undergoing cardiac surgery; VSMC were isolated from their saphenous veins to perform in vitro assays and microarrays. Study 2 included 11 patients with CAD; IMA were treated ex vivo with Wnt5a recombinant protein (rWnt5a) to perform western blot (WB) analyses. Study 3 included 647 patients with CAD; RNA sequencing was performed on samples from their internal mammary arteries (IMA), IMA perivascular adipose (PVAT), and thoracic adipose tissue (ThAT). VSMC and human aortic smooth muscle cells (HASMC) from healthy donors were grown in osteogenic medium in the presence or absence of rWnt5a with or without specific protein inhibitors. Calcium deposition and expression of VC markers (i.e. RUNX2, BMP2, and MSX2) were assessed with a colorimetric assay and by RT-qPCR, respectively. Phosphorylation/activation of non-canonical Wnt pathway effectors was evaluated by WB analyses. Results rWnt5a treatment significantly increased calcium deposition in both VSMC and HASMC at a concentration that activates both JNK and CaMKII, that are effectors of the non-canonical planar cell polarity pathway and the calcium-dependent pathway, respectively. Inhibition of either JNK or CaMKII could not counteract rWnt5a-mediated increase in VSMC calcium deposition; whereas, inhibition of both non-canonical pathway effectors (JNK-i and CaMKII-i) prevented rWnt5a-mediated increase in calcium deposition by VSMC (A) and HASMC. Inhibition of JNK and CaMKII also prevented rWnt5a-induced gene expression of VC markers, such as RUNX2 (B). rWnt5a treatment in IMA increased the activation of JNK and CaMKII. Patients with higher WNT5A levels in IMA had significantly higher RUNX2 levels. By intersecting RNA sequencing and microarray data complement 3 (C3) resulted as the most upregulated gene in rWnt5a-treated VSMC among those genes whose levels positively correlated in IMA with both WNT5A and RUNX2 expression (C). Patients with higher WNT5A levels in IMA, their PVAT, and ThAT had significantly higher C3 levels (D), and patients with higher levels of C3AR1, that is the gene coding for the C3a receptor, had higher VC markers expression. C3 inhibition (C3-i) with a C3AR1 antagonist counteracted Wnt5a-induced VSMC calcium deposition (E). Conclusions Non-canonical Wnt signalling promotes VSMC calcification through C3. Wnt5a may be a therapeutic target in VC Figure

Wnt signaling contributes to vascular calcification by induction of matrix metalloproteinases

Activation of Arterial Matrix Metalloproteinases Leads to Vascular Calcification in Chronic Kidney Disease

Wnt Signaling in Vascular Calcification

Wnt1 inhibits vascular smooth muscle cell calcification by promoting ANKH expression.

Vascular Calcification in Chronic Kidney Disease is Induced by Bone Morphogenetic Protein-2 Via a Mechanism Involving the Wnt/β-Catenin Pathway

Activation of the IKK2/NF-κB pathway in VSMCs inhibits calcified vascular stiffness in CKD

Vascular Calcification is Associated with Wnt-signaling Pathway and Blood Pressure Variability in Chronic Kidney Disease Rats.

Sclerostin is Involved in Osteogenic Transdifferentiation of Vascular Smooth Muscle Cells in Chronic Kidney Disease-Associated Vascular Calcification with Non-Canonical Wnt Signaling.

[Extracellular Matrix, Matrix-Degrading Proteases and Vascular Calcification].

High phosphorus level leads to aortic calcification via β-catenin in chronic kidney disease

Exosomal STAT1 derived from high phosphorus-stimulated vascular endothelial cells induces vascular smooth muscle cell calcification via the Wnt/-catenin signaling pathway

Mechanisms of the Osteogenic Switch of Smooth Muscle Cells in Vascular Calcification: WNT Signaling, BMPs, Mechanotransduction, and EndMT

Cell-Matrix Interactions and Matricrine Signaling in the Pathogenesis of Vascular Calcification

Klotho/FGF23 axis mediates high phosphate‐induced vascular calcification in vascular smooth muscle cells via Wnt7b/β‐catenin pathway

High Phosphate-Induced JAK-STAT Signalling Sustains Vascular Smooth Muscle Cell Inflammation and Limits Calcification

CKAP4 Contributes to the Progression of Vascular Calcification (VC) in Chronic Kidney Disease (CKD) by Modulating YAP Phosphorylation and MMP2 Expression

CCAAT/Enhancer-Binding Protein Alpha Is a Novel Regulator of Vascular Smooth Muscle Cell Osteochondrogenic Transition and Vascular Calcification

Impaired arterial vitamin D signaling occurs in the development of vascular calcification

Increased β-adrenergic stimulation augments vascular smooth muscle cell calcification via PKA/CREB signalling

Osteocalcin Regulates Arterial Calcification Via Altered Wnt Signaling and Glucose Metabolism

The novel role of complement 3 in Wnt5a-mediated vascular smooth muscle cell calcification